Insider Transaction Report for Avalo Therapeutics, Inc.

Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., reported a series of transactions on March 28, 2026. He acquired 24,200 shares of Common Stock through the conversion of Restricted Stock Units (RSUs), with a transaction price of $0.00 per share. Following this acquisition, his total holdings increased to 41,538 shares. Subsequently, Mr. Sullivan disposed of 8,241 shares of Common Stock at a price of $13.89 per share, reducing his post-transaction holdings to 33,297 shares. These RSUs were granted on August 13, 2024, with vesting scheduled in three equal tranches on March 28, 2025, March 28, 2026, and March 28, 2027, contingent upon continued service. The conversion of RSUs into common stock occurred on a one-to-one basis.